Journey with Trajan
At every step, our journey is guided by a commitment to advancing science that benefits people—from developing breakthrough technologies, expanding global capabilities, or supporting research that improves human health and wellbeing.
2010
An idea takes root
Trajan Scientific and Medical (Trajan) began with a simple yet powerful question asked around the Tomisich family’s kitchen table, “How can we make a positive impact on society?”
The answer combined their passion for science and history, to create a new business inspired by the Roman emperor Trajan, whose legacy was built on serving the greater good.
2011
A foundation built on science and purpose
Founded by Angela and Stephen Tomisich—scientists with deep roots in analytical chemistry and biomedical science—Trajan began as a self-funded venture with a bold mission: to enrich human wellbeing through scientific measurement.
Impact
“Our work highlighted an opportunity to enable individuals to better understand their health and wellbeing through data; delivering science that could truly benefit people.” — Stephen Tomisich, Group CEO and Managing Director
2011
The journey begins
Trajan Scientific and Medical global corporate headquarters are established in Melbourne, Australia.
Trajan’s first acquisition of Grale Scientific in Melbourne provides immediate connection to the healthcare system through supply of consumable products.
Impact
Trajan’s pathology portfolio supports healthcare professionals to get results for patients more efficiently.
2013
Expanding nationally and globally
HD Scientific consumables business in Sydney, Australia is acquired and merged with subsidiary Grale Scientific, trading as Grale HDS.
SGE Analytical Science is acquired, extending Trajan’s footprint beyond Australia, to the UK, US and Japan, through global supply of analytical products leveraging precision glass technology.
SciMed Precision is established in Melbourne Australia as a new subsidiary of the Trajan group.
Impact
Trajan is able to deliver more sensitive, selective and affordable analysis solutions worldwide for biological, food and environmental samples.
2014
Integration and innovation
Trajan integrates its subsidiaries and launches new collaborations, strengthening its unique product and technology offerings.
Trajan funded the development of a Skin Health Program - a collaboration between the Royal District Nursing Service (now Bolton Clarke) and Council on the Ageing, Victoria, Australia.
The Australian Government committed A$2.1 million to Trajan and University of Tasmania to partly fund a new Australian Research Council Industrial Transformation Training Centre for Portable Analytical Separation Technologies (ASTech).
Impact
Numerous technologies emerge in 2014, with some still to be commercialized. Others now available, such as Trajan’s hemaPEN® and Versiti are designed to enable accurate collection and analysis of samples on the go.
2015
Advancing manufacturing and new locations
Trajan opens Global Commercial Office in Chester, UK.
Trajan opens new Instruments, Sensors and Devices business unit, co-located at University of Adelaide's Institute for Photonics and Advanced Sensing (IPAS), South Australia, with support from the South Australian Government.
Australian Government awards Next Generation Manufacturing and Investment Programme Grant to Trajan.
Impact
Trajan’s investment in advanced manufacturing of precision scientific and medical glass expanded opportunities for the medical device sector through research technologies.
Trajan's first Trajan-branded product is launched – premium quality microscope slides to address an unmet need for high-performing adhesive microscope slides.
Impact
Today, Trajan’s microscope slides are used globally to provide efficient and reliable analysis of samples, such as breast tissue, to inform patient’s cancer treatments.
2016
Collaborations and acquisitions
Trajan acquires Barons Medical Consulting (Melbourne, Australia) to drive growth of new technologies.
Trajan was awarded an Australian Research Council (ARC) Linkage Grant, recognized for Excellence in Research Collaboration, and expanded ASTech to include the University of South Australia.
Trajan becomes point of contact for the Grace Davisil Silica business in Australia and New Zealand, and Chem Service Analytical Standards range previously handled by Grace.
In North America, Trajan established a collaboration with Queen’s University and Université Laval in Canada.
Trajan opens new Americas hub in Austin, USA; and acquires Epic Extrusion assets to establish precision polymer tubing manufacturing facility in San Diego, CA, USA.
Trajan acquires LEAP Technologies (Carrboro, North Carolina, USA), extending capabilities into laboratory automation.
Impact
With the acquisition of engineering automation group LEAP, laboratories can now easily adopt new disruptive chemistry and microsampling technologies for more precision in drug discovery, and environmental and food monitoring. Resulting work in HDX is used by major global companies in protein research including important drug discovery and development.
2017
Further growth and a foray into nutritional health
Trajan invests in Trajan Nutrition. Health Delivered, and LBPR, promoting pathways to better nutrition.
Trajan opens a new manufacturing facility in Penang, Malaysia.
Impact
Trajan's new ventures expand its reach into new healthcare arenas, while its facility in Southeast Asia provides manufacturing excellence and builds on its capacity for quick response to customers.
2018
Modernizing science delivery
Trajan announces acquisition of Soltec Inc in Bethel, CT, USA, to enhance capability across silicon materials and technologies.
Trajan partners with Sierra Analytics to provide joint HDX solution, innovating in laboratory automation.
Trajan invests in ARC Centre for Personalised Therapeutics Technologies (ARC CPTT).
Impact
Expanding delivery by modernizing processes, improving manufacturing and making new technologies more accessible to laboratories. “We hope to promote the same collaborative and commercial success in the medtech and pharmaceutical (MTP) sector that we have been nurturing in analytical science.” — Stephen Tomisich, Group CEO and Managing Director
2019
Supporting research
Trajan funds research with Bolton Clarke Research Institute and RMIT University to explore thermal imaging techniques for predicting wound healing.
Impact
Health professionals could identify slower healing wounds early and provide additional help to speed the healing process. The opportunity for proactive management and prevention of other related problems.
2020
Advances in microsampling and MS
Trajan’s hemaPEN® receives a European patent, US FDA listing as a blood microsampling device, CE mark for diagnostic use across EU and the UK, and inclusion on TGA’s ARTG as the first blood microsampling device for use in Australia.
Trajan and Queen’s University awarded Mitacs Grant to develop multiple electrospray (MES) technology for mass spectrometry.
Impact
Widespread distribution and adoption of portable microsampling technologies enabling precise microsample collection. The hemaPEN design allows blood spot sampling from any angle and makes it nearly impossible to under- or over-sample, locking the blood samples inside the device after sample collection preventing contamination or tampering. Emitters are used in high sensitivity LCMS in a wide range of research applications, such as environmental monitoring, biomedical applications, drug discovery and therapeutic drug monitoring. Compared to current emitters available on the market, MES emitters are predicted to provide more efficient ion generation, most notably in the field of proteomics.
2021
IPO and strategic acquisitions
Trajan becomes a publicly listed company, raising $50M to fuel further growth.
Trajan acquires Neoteryx, LLC, a US-based developer of microsampling products, MyHealthTest blood testing service in Australia, US-based LEAP PAL Parts and Consumables, LLC, and Axel Semrau, a laboratory automation, chromatography, and software business in Germany.
Impact
Neoteryx Mitra® with VAMS technology complements and expanded Trajan’s microsampling offering of innovative and precise alternatives to traditional blood collection methods. Acquisition of blood testing operations highlighted the importance of sample integrity in data-based preventative healthcare, enabling wellness monitoring and promoting personalized, accessible healthcare. "Trajan acquired the business of LEAP Technologies in 2016. Originally LEAP Technologies and LPP were two parts of one business; the former developing automated workflows and providing the capital equipment solutions, the latter delivering the parts, supplies, and consumables to support those platforms. In 2010 the two were split. With the acquisition of LPP Trajan brings the two parts of that business back together again to provide an integrated and streamlined customer support capability." — Stephen Tomisich, Group CEO and Managing Director “Axel Semrau owns and develops the CHRONOS intelligent sequencing software platform upon which Trajan’s automated workflows are built. We intend to further invest in CHRONOS in line with Trajan’s goal to simplify and automate complex analytical workflows.” — Stephen Tomisich, Group CEO and Managing Director.
2022
Enhancing GC sample introduction
Trajan acquires Chromatography Research Supplies (CRS), a leading global manufacturer of high-quality analytical consumables based in Louisville, Kentucky, USA. CRS is considered industry best practice in both product performance and fabrication capabilities of electronic and manual crimping tools, gas filters, ferrules, GC septa, and well plates.
Impact
“CRS and Trajan are a natural fit through product offerings as well as a company vision that places value on our employees and strives to leave the world in a better place than when we found it.” — Debbie Clark, Global Account Manager (formerly VP, CRS)
2023
Strengthening software suite
Trajan acquires HDExaminer Software from California-based, Sierra Analytics Inc. complementing its laboratory automation offering. HDExaminer enables the analysis of the protein structural information generated by the Mass Spectrometer.
Impact
“Bringing ownership of HDExaminer into the Trajan family allows us to invest in the future development and enhancement of this powerful analytical platform. Together with our growing number of leading collaborators in the field of HDX-MS we expect to target several areas of the package to enable broader adoption of the technique along with enhancing the depth and value of protein structural information that can be revealed.” — Stephen Tomisich, Group CEO and Managing Director.
2024
Refined focus
Through strategic analysis and collaboration with stakeholders, Trajan continually refines its offerings to meet real-world needs.
Trajan’s products and services are thoughtfully organized into key application areas:
- Clinical – advancing diagnostics and patient care
- Environmental – supporting monitoring and preservation for a healthier planet
- Pharmaceutical – development and quality control solutions
- Food – ensuring quality and safety from farm to table
This structure aligns the team’s focus to innovate where it matters most.
2025
Looking ahead
Additional content TBC
As Trajan Scientific and Medical continues to evolve, our focus remains clear: to enrich personal health through scientific tools and solutions.
Join us as we shape what’s next - driven by purpose, powered by science, and focused on making a positive impact on human wellbeing.